Home › Compare › LOQPF vs ABBV
LOQPF yields 59.70% · ABBV yields 3.06%● Live data
📍 LOQPF pulled ahead of the other in Year 1
Combined, LOQPF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of LOQPF + ABBV for your $10,000?
accesso Technology Group plc, together with its subsidiaries, develops technology solutions for the attractions and leisure industry in the United Kingdom, other European countries, Australia, the South Pacific, the United States, Canada, and Central and South America. The company operates through Ticketing and Distribution, and Guest Experience segments. It offers ticketing solutions for fairs and festivals, performing arts, ski, theme parks, tours and attractions, water parks, and zoos and aquariums, as well as cultural facilities. The company also offers various solutions, such as accesso LoQueue, a virtual queuing solution; the experience engine, an experience management platform; and accesso Passport ticketing suite, which provides season pass, group tickets, meal vouchers, and other services. In addition, it provides accesso Siriusware, which offers software solutions comprising ticketing and admissions, memberships, reservations, resource scheduling, retail, food service, gift cards, kiosks, and ecommerce; and accesso ShoWare ticketing solutions for box office, kiosk, online, mobile, call center, and social media sales. The company was formerly known as Lo-Q plc and changed its name to accesso Technology Group plc in November 2013. accesso Technology Group plc was incorporated in 2000 and is based in Twyford, the United Kingdom.
Full LOQPF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.